Metastatic Breast Cancer

Trastuzumab deruxtecan reduced risk for disease progression or death compared with trastuzumab emtansine among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.

A phase 3 study of sacituzumab govitecan-hziy met its primary endpoint of PFS among a subset of patients with hormone receptor-positive, HER2-negative metastatic breast cancer, according to topline data released by the agent’s manufacturer.

Three of six women with metastatic breast cancer who received investigational tumor-infiltrating lymphocytes plus pembrolizumab demonstrated tumor reductions greater than 50%, according to phase 2 study results.

Fam-trastuzumab deruxtecan-nxki improved outcomes among patients with HER2-low unresectable or metastatic breast cancer, according to topline data released by the agent’s manufacturer.

The FDA granted fast track designation to gedatolisib for treatment of certain patients with breast cancer.

Ian E. Krop, MD, PhD, associate chief of the division of breast oncology in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, spoke with Healio about recent findings from the DESTINY-Breast03 trial.

Samuraciclib plus fulvestrant demonstrated durable efficacy among a small cohort of women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

The addition of pembrolizumab to first-line chemotherapy conferred clinically meaningful benefit to patients with inoperable or metastatic triple-negative breast cancer, according to results presented at San Antonio Breast Cancer Symposium.

Pyrotinib plus capecitabine prolonged OS and PFS compared with lapatinib-capecitabine among patients with pretreated HER2-positive metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

A liquid biopsy-based approach to treatment selection improved outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.